Risankizumab improves skin appearance in patients with plaque psoriasis
Treatment with risankizumab, an interleukin-23 inhibitor, significantly improves skin appearance in patients with moderate-to-severe plaque psoriasis, according to the IMMvent* study presented at the Inflammatory Skin Disease Summit (ISDS).
The phase III, double-blind trial involved 605 patients with moderate-to-severe plaque psoriasis who were randomized in a 1:1 ratio to receive either risankizumab 150 mg for week 0, 4, 16, and 28 or adalimumab 80 mg as initial dose, then followed by 40 mg every other week from week 1. The study’s co-primary outcomes were achievement of PASI** 90 (defined as 90 percent skin improvement in the PASI) and sPGA*** 0/1 (defined as score of clear/almost clear skin) response rates at 16 weeks. [ISDS 2018, abstract 18]
At 16 weeks, significantly more patients treated with risankizumab achieved PASI 90 and sPGA 0/1 responses compared with adalimumab (72.4 percent vs 47.4 percent; p<0.001 and 83.7 percent vs 60.2 percent; p<0.001, respectively).
A significantly higher percentage of patients in the risankizumab group also achieved a PASI 100 response than those in the adalimumab group at 16 weeks (39.9 percent vs 23.0 percent; p<0.001).
Patients in the adalimumab group who achieved responses less than PASI 90 but more than PASI 50 at 16 weeks were rerandomized to either switching to risankizumab or continuing treatment with adalimumab.
After rerandomization, majority of the patients who were switched to risankizumab achieved PASI 90 and PASI 100 responses at week 44 compared with those who continued adalimumab (66.0 percent vs 21.4 percent and 39.6 percent vs 7.1 percent, respectively).
There were no significant differences between the risankizumab and the adalimumab groups in the treatment-emergent adverse event rates for both randomized phases.
“Risankizumab treatment showed greater clinical responses vs adalimumab in adult patients with moderate-to severe plaque psoriasis,” said Dr Kristian Reich from Dermatologikum Berlin and SCIderm Research Institute in Hamburg, Germany, who also noted that “no additional safety concerns were identified in patients who [were] switched from adalimumab to risankizumab.”
*IMMvent: BI 655066/ABBV-066 (risankizumab) compared to active comparator (adalimumab) in patients with moderate to severe chronic plaque psoriasis
**PASI: Psoriasis Area Severity Index
***sPGA: static Physician’s Global Assessment